Dr Reddy’s Laboratories Q2 Results 2025 Highlights: Net Profit Surged by 7.28% & Revenue Up 9.83% YoY

Click and Sign Up to Get Live Updates on Q2 Results 

Dr Reddy’s Laboratories Q2 Results FY26: During Q2 FY26, Dr Reddy’s Laboratories’ profit increased 7.28% YoY, while revenue increased by 9.83% YoY. The company posted robust numbers, with Q2 PAT at ₹1,347.10 crores and revenue at ₹8,828.30 crores. Dr Reddy’s Laboratories showed its Q2 results on 24th October 2025.  

Dr Reddy’s Laboratories Q2 Results FY26: Extracts of FY25 & FY26

Dr Reddy’s Laboratories Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

• Dr Reddy’s Laboratories clocked Q2 FY26 consolidated revenue of ₹8,828.30 crores vs ₹8,038.20 crores. 
• On the profit front, Dr Reddy’s Laboratories earned a consolidated PAT of ₹1,347.10 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹1,255.70 crore.
• According to the consolidated figures, Dr Reddy’s Laboratories’ quarterly PAT increased by 7.28% YoY, while revenue increased by 9.83%.
• Dr Reddy’s Laboratories clocked Q2 FY26 standalone revenue of ₹4,618.60 crores vs ₹6,696.30 crores. 
• On the profit front, Dr Reddy’s Laboratories earned a standalone PAT of ₹387.30 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹1,882.10 crore.
• According to the standalone figures, Dr Reddy’s Laboratories’ quarterly PAT decreased by 31.03% YoY, while revenue decreased by 79.42%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Dr Reddy’s Laboratories Share Price Performance

On the opening bell on 27th October 2025, Dr Reddy’s Laboratories shares opened at ₹1,278.00 per share. However, the initial gains have since eroded, and Dr Reddy’s Laboratories shares are trading at ₹1,285.00 per share, below the opening price.   

Considering the long-term achievements, Dr Reddy’s Laboratories shares have yielded close to 7.20% returns in the past 6 months, and 1-year returns stand at -2.02%. Over the maximum timeframe, Dr Reddy’s Laboratories shares delivered a 25,295.26% return to investors. 

What Analysts Expect Post Q2 Results?

Following Dr Reddy’s Laboratories’ robust Q2 results for FY26, analysts expect its share price to rise. According to analysts, Dr Reddy’s Laboratories’ share price could reach ₹1,420.30 per share in the coming year and, in a downturn, could hit ₹1,250.30 per share. However, one must ignore stock market volatility and invest in Dr Reddy’s Laboratories after thorough research. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY

Inspira Enterprise India IPO Details: Everything You Should Know about 

Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY

HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY

BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here